Cystic kidneys are common causes of end-stage renal disease, both in children and in
adults. Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive …

Autosomal-dominant polycystic kidney disease (ADPKD) affects up to 12 million individuals
and is the fourth most common cause for renal replacement therapy worldwide. There have …

Approval of the vasopressin V2 receptor antagonist tolvaptan—based on the landmark
TEMPO 3: 4 trial—marked a transformation in the management of autosomal dominant …

Background Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of
end-stage renal disease, but estimates of its prevalence vary by> 10-fold. The objective of …

Autosomal dominant polycystic kidney disease is the most common inherited kidney disease
and accounts for 7–10% of all patients on renal replacement therapy worldwide. Although …

Abstract Recently, the European Medicines Agency approved the use of the vasopressin V2
receptor antagonist tolvaptan to slow the progression of cyst development and renal …

Renal disease variability in autosomal dominant polycystic kidney disease (ADPKD) is
strongly influenced by the gene locus (PKD1 versus PKD2). Recent studies identified …

Importance Autosomal dominant polycystic kidney disease (ADPKD) is characterized by
progressive cyst formation in both kidneys and loss of renal function, eventually leading to a …

BACKGROUND A treatment option for autosomal dominant polycystic kidney disease
(ADPKD) has highlighted the need to identify rapidly progressive patients. Kidney size/age …

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal
disease, with an estimated prevalence between 1: 1000 and 1: 2500. It is mostly caused by …